Current drug therapies for rosacea: A chronic vascular and inflammatory skin disease

Journal of Managed Care Pharmacy

Volumn 20, Issue 6, 2014, Pages 623-629

  Feldman, Steven R ^a   Huang, William W ^a   Huynh, Tu T ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Galderma Laboratories LP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZELAIC ACID; BRIMONIDINE; DOXYCYCLINE; METRONIDAZOLE; SULFACETAMIDE PLUS SULFUR; TETRACYCLINE DERIVATIVE; CATHELICIDIN; KALLIKREIN 5; TETRACYCLINE; TOLL LIKE RECEPTOR 2; ANTIINFLAMMATORY AGENT; DERMATOLOGICAL AGENT;

ARTICLE; CHRONIC DISEASE; CHRONIC INFLAMMATION; CLINICAL FEATURE; DERMATITIS; HUMAN; PATHOPHYSIOLOGY; ROSACEA; TREATMENT PLANNING; VASCULAR DISEASE; VASODILATATION; FACE ERYTHEMA; MULTICENTER STUDY (TOPIC); PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN BLOOD VESSEL DISORDER; TOPICAL TREATMENT; COMPLICATION; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; CHRONIC DISEASE; DERMATOLOGIC AGENTS; HUMANS; ROSACEA; TREATMENT OUTCOME;

EID: 84901194474     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2014.20.6.623     Document Type: Article

References (86)

1. National Rosacea Society. If you have rosacea, you're not alone. 2014. Available at: http://www.rosacea.org/patients/index.php. Accessed April 21, 2014.
2. Maier LE. Rosacea: advances in understanding pathogenesis and treatment. J Clin Invest. 2011;1(5):739-55.
3. Odom RB. The subtypes of rosacea: implications for treatment. Cutis. 2004;73(1 Suppl):9-14.
4. Sant GR, Kempuraj D, Marchand JE, Theoharides TC. The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urology. 2007;69(4 Suppl):34-40.
5. Goldgar C, Keahey D, Houchins J. Treatment options for acne rosacea. Am Fam Physician. 2009;80(5):461-68.
6. Bergfeld WF. A lifetime of healthy skin: implications for women. Int J Fertil Womens Med. 1999;44(2):83-95.
7. Gupta AK, Chaudhry MM. Rosacea and its management: an overview. J Eur Acad Dermatol Venereol. 2005;19(3):273-85.
8. Drolet B, Paller AS. Childhood rosacea. Pediatr Dermatol. 1992;9(1):22-26.
9. Aksoy B, Altaykan-Hapa A, Egemen D, Karagoz F, Atakan N. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol. 2010;163(4):719-25.
10. Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest. 2002;110(6):851-60.
11. Alexis AF. Rosacea in patients with skin of color: uncommon but not rare. Cutis. 2010;86(2):60-62.
12. Rosen T, Stone MS. Acne rosacea in blacks. J Am Acad Dermatol. 1987;17(1):70-73.
13. Heiberger K, Brenman S. Common triggers of facial erythema in adults. JAAPA. 2001;14(9):49-50, 53-54.
14. Landow K. Unraveling the mystery of rosacea. Keys to getting the red out. Postgrad Med. 2002;112(6):51-58, 82.
15. Boni-Schnetzler M, Thorne J, Parnaud G, et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab. 2008;93(10):4065-74.
16. Su D, Drummond PD. Blushing propensity and psychological distress in people with rosacea. Clin Psychol Psychother. 2012;19(6):488-95.
17. Wilkin JK. Rosacea. Pathophysiology and treatment. Arch Dermatol. 1994;130(3):359-62.
18. Blount BW, Pelletier AL. Rosacea: a common, yet commonly overlooked, condition. Am Fam Physician. 2002;66(3):435-40.
19. Yamasaki K, Gallo RL. Rosacea as a disease of cathelicidins and skin innate immunity. J Investig Dermatol Symp Proc. 2011;15(1):12-15.
20. Cribier B. Pathophysiology of rosacea: redness, telangiectasia, and rosacea. Ann Dermatol Venereol. 2011;138(Suppl 3):S184-S91.
21. Di Nardo A, Vitiello A, Gallo RL. Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J Immunol. 2003;170(5):2274-78.
22. Nizet V, Ohtake T, Lauth X, et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature. 2001;414(6862):454-57.
23. Reinholz M, Ruzicka T, Schauber J. Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease. Ann Dermatol. 2012;24(2):126-35.
24. Morizane S, Yamasaki K, Kabigting FD, Gallo RL. Kallikrein expression and cathelicidin processing are independently controlled in keratinocytes by calcium, vitamin D(3), and retinoic acid. J Invest Dermatol. 2010;130(5):1297-306.
25. Schauber J, Gallo RL. Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol. 2009;124(3 Suppl 2):R13-18.
26. Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest. 2003;111(11):1665-72.
27. Braff MH, Zaiou M, Fierer J, Nizet V, Gallo RL. Keratinocyte production of cathelicidin provides direct activity against bacterial skin pathogens. Infect Immun. 2005;73(10):6771-81.
28. Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13(8):975-80.
29. Ny A, Egelrud T. Epidermal hyperproliferation and decreased skin barrier function in mice overexpressing stratum corneum chymotryptic enzyme. Acta Derm Venereol. 2004;84(1):18-22.
30. Yamasaki K, Kanada K, Macleod DT, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol. 2011;131(3):688-97.
31. Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by Tolllike receptors and hyaluronan. Nat Med. 2005;11(11):1173-79.
32. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-76.
33. Aroni K, Tsagroni E, Kavantzas N, Patsouris E, Ioannidis E. A study of the pathogenesis of rosacea: how angiogenesis and mast cells may participate in a complex multifactorial process. Arch Dermatol Res. 2008;300(3):125-31.
34. Steinhoff M, Buddenkotte J, Aubert J, et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15(1):2-11.
35. Reich A, Wojcik-Maciejewicz A, Slominski AT. Stress and the skin. G Ital Dermatol Venereol. 2010;145(2):213-19.
36. Shenefelt PD. Biofeedback, cognitive-behavioral methods, and hypnosis in dermatology: is it all in your mind? Dermatol Ther. 2003;16(2):114-22.
37. Kanada KN, Nakatsuji T, Gallo RL. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin. J Invest Dermatol. 2012;132(5):1435-42.
38. Fowler J Jr, Jackson M, Moore A, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;12(6):650-56.
39. Fowler J, Jarratt M, Moore A, et al. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol. 2012;166(3):633-41.
40. Shanler SD, Ondo AL. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol. 2007;143(11):1369-71.
41. Parodi A, Drago F, Paolino S, Cozzani E, Gallo R. Treatment of rosacea. Ann Dermatol Venereol. 2011;138(Suppl 3):S211-S14.
42. Baldwin HE. Diagnosis and treatment of rosacea: state of the art. J Drugs Dermatol. 2012;11(6):725-30.
43. METROGEL (metronidazole) gel, 0.75% [prescribing information]. Galderma Laboratories, L.P. 2004.
44. METROGEL (metronidazole) gel, 1%. Galderma Laboratories, L.P. Revised October 2011. Available at: http://www.metrogel.com/downloads/ Metrogel-PI.pdf. Accessed April 21, 2014.
45. FINACEA (azelaic acid) gel, 15%. Bayer HealthCare Pharmaceuticals Inc. Revised April 2014. Available at: http://labeling.bayerhealthcare.com/html/ products/pi/Finacea_PI.pdf. Accessed April 21, 2014.
46. Sodium Sulfacetamide 10% and Sulfur 5% lotion. Perrigo. Revised October 2007. Available at: http://dailymed.nlm.nih.gov/dailymed/lookup. cfm?setid=3b9c6ea7-b0f4-4799-b809-bf22d4c29b4e. Accessed April 22, 2014.
47. Sodium Sulfacetamide 10% and Sulfur 5% emollient cream. Austin Pharmaceuticals, LLC. Revised April 2012. Available at: http://dailymed. nlm.nih.gov/dailymed/lookup.cfm?setid=701e8b26-2dee-4c11-a3d0-256ad530dccc. Accessed April 22, 2014.
48. Mirvaso (brimonidine) topical gel, 0.33%. Galderma Laboratories, L.P. 2013. Available at: http://www.mirvaso.com/?utm_source=google&utm_ medium=cpc&utm_term=mirvaso&utm_campaign=Brand+Mirvaso&utm_ content=sbJM4wbXx|dc_pcrid_31180033105_pkw_mirvaso_pmt_e. Accessed May 1, 2014.
49. Oracea (doxycycline, USP) capsules 40 mg (30 mg immediate release and 10 mg delayed release beads). Galderma Laboratories, L.P. 2013. Available at: http://www.oracea.com/. Accessed May 1, 2014.
50. McClellan KJ, Noble S. Topical metronidazole. A review of its use in rosacea. Am J Clin Dermatol. 2000;1(3):191-99.
51. Del Rosso JQ, Baldwin H, Webster G. American Acne & Rosacea Society. American Acne & Rosacea Society rosacea medical management guidelines. J Drugs Dermatol. 2008;7(6):531-33. Available at: http://www.ncbi.nlm.nih. gov/pubmed/18561582. Accessed May 2, 2014.
52. NORITATE (metronidazole cream) 1% [package insert]. Dermik Laboratories. December 2006. Available at: http://dailymed.nlm.nih.gov/ dailymed/lookup.cfm?setid=1787c491-d92c-4239-9d9f-6a91b629835d. Accessed May 5, 2014.
53. Narayanan S, Hunerbein A, Getie M, Jackel A, Neubert RH. Scavenging properties of metronidazole on free oxygen radicals in a skin lipid model system. J Pharm Pharmacol. 2007;59(8):1125-30.
54. Wolf JE Jr, Kerrouche N, Arsonnaud S. Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis. 2006;77(4 Suppl):3-11.
55. Dahl MV, Jarratt M, Kaplan D, Tuley MR, Baker MD. Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea. J Am Acad Dermatol. 2001;45(5):723-30.
56. Breneman DL, Stewart D, Hevia O, Hino PD, Drake LA. A double-blind, multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis. 1998;61(1):44-47.
57. Jorizzo JL, Lebwohl M, Tobey RE. The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double-blind clinical trial. J Am Acad Dermatol. 1998;39(3):502-04.
58. Tromp G, Kuivaniemi H, Raphael S, et al. Genetic linkage of familial granulomatous inflammatory arthritis, skin rash, and uveitis to chromosome 16. Am J Hum Genet. 1996;59(5):1097-107.
59. Leeming JP, Holland KT, Bojar RA. The in vitro antimicrobial effect of azelaic acid. Br J Dermatol. 1986;115(5):551-56.
60. Emer J, Waldorf H, Berson D. Botanicals and anti-inflammatories: natural ingredients for rosacea. Semin Cutan Med Surg. 2011;30(3):148-55.
61. Mayer-da-Silva A, Gollnick H, Detmar M, et al. Effects of azelaic acid on sebaceous gland, sebum excretion rate and keratinization pattern in human skin. An in vivo and in vitro study. Acta Derm Venereol Suppl (Stockh). 1989;143:20-30.
62. Gollnick H, Layton A. Azelaic acid 15% gel in the treatment of rosacea. Expert Opin Pharmacother. 2008;9(15):2699-706.
63. Thiboutot DM, Fleischer AB, Jr., Del Rosso JQ, Graupe K. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol. 2008;7(6):541-46.
64. Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139(11):1444-50.
65. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48(6):836-45.
66. [No authors listed]. Azelaic acid (Finacea) for rosacea. Med Lett Drugs Ther. 2003;45(1165):76.
67. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 2004;20(3):319-25.
68. Coda AB, Hata T, Miller J, et al. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol. 2013;69(4):570-77.
69. Thiboutot DM, Weiss J, Bucko A, et al. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol. 2007;57(5):791-99.
70. Gupta AK, Nicol K. The use of sulfur in dermatology. J Drugs Dermatol. 2004;3(4):427-31.
71. Del Rosso JQ. Evaluating the role of topical therapies in the management of rosacea: focus on combination sodium sulfacetamide and sulfur formulations. Cutis. 2004;73(1 Suppl):29-33
72. Sauder D, Miller R, Gratton D, Danby W, Griffiths C, Phillips S. The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double-blind study. J Dermatolog Treat. 1997;8(2):79-85.
73. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54(2):258-65.
74. Griffin MO, Fricovsky E, Ceballos G, Villarreal F. Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol. 2010;299(3):C539-48.
75. Alikhan A, Kurek L, Feldman SR. The role of tetracyclines in rosacea. Am J Clin Dermatol. 2010;11(2):79-87.
76. Sloan B, Scheinfeld N. The use and safety of doxycycline hyclate and other second-generation tetracyclines. Expert Opin Drug Saf. 2008;7(5):571-77.
77. Weinberg JM. The anti-inflammatory effects of tetracyclines. Cutis. 2005;75(4 Suppl):6-11.
78. Berman B, Zell D. Subantimicrobial dose doxycycline: a unique treatment for rosacea. Cutis. 2005;75(4 Suppl):19-24.
79. McKeage K, Deeks ED. Doxycycline 40 mg capsules (30 mg immediaterelease/ 10 mg delayed-release beads): anti-inflammatory dose in rosacea. Am J Clin Dermatol. 2010;11(3):217-22.
80. Webster GF. An open-label, community-based, 12-week assessment of the effectiveness and safety of monotherapy with doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads). Cutis. 2010;86(5 Suppl):7-15.
81. Theobald K, Bradshaw M, Leyden J. Anti-inflammatory dose doxycycline (40 mg controlled-release) confers maximum anti-inflammatory efficacy in rosacea. Skinmed. 2007;6(5):221-26.
82. Preshaw P, Novak M, Mellonig J, et al. Modified-release subantimicrobial dose doxycycline enhances scaling and root planning in subjects with periodontal disease. J Periodontol. 2008;79(3):440-52.
83. Del Rosso JQ. The ORCA (Oracea for rosacea: a community-based assessment) trial: a large-scale, phase 4 trial in papulopustular rosacea. Cutis. 2010;86(5 Suppl):4-6.
84. Del Rosso JQ. Anti-inflamatory dose doxycycline in the treatment of rosacea. J Drugs Dermatol. 2009;8(7):664-68.
85. Garcia RA, Pantazatos DP, Gessner CR, Go KV, Woods VL Jr, Villarreal FJ. Molecular interactions between matrilysin and the matrix metalloproteinase inhibitor doxycycline investigated by deuterium exchange mass spectrometry. Mol Pharmacol. 2005;67(4):1128-36.
86. Roosta N, Black DS, Peng D, Riley LW. Skin disease and stigma in emerging adulthood: impact on healthy development. J Cutan Med Surg. 2010;14(6):285-90.